Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors
Kole T. Roybal, Jasper Z. Williams, Leonardo Morsut, et al.
Cell (2016) Vol. 167, Iss. 2, pp. 419-432.e16
Open Access | Times Cited: 584

Showing 1-25 of 584 citing articles:

The Principles of Engineering Immune Cells to Treat Cancer
Wendell A. Lim, Carl H. June
Cell (2017) Vol. 168, Iss. 4, pp. 724-740
Open Access | Times Cited: 970
Notch Signaling in Development, Tissue Homeostasis, and Disease
Chris Siebel, Urban Lendahl
Physiological Reviews (2017) Vol. 97, Iss. 4, pp. 1235-1294
Open Access | Times Cited: 841
Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies
Kristin G. Anderson, Ingunn M. Stromnes, Philip D. Greenberg
Cancer Cell (2017) Vol. 31, Iss. 3, pp. 311-325
Open Access | Times Cited: 599
Treg cell-based therapies: challenges and perspectives
Caroline Raffin, Linda T. Vo, Jeffrey A. Bluestone
Nature reviews. Immunology (2019) Vol. 20, Iss. 3, pp. 158-172
Open Access | Times Cited: 538
Is autoimmunity the Achilles' heel of cancer immunotherapy?
Carl H. June, Jeremy Warshauer, Jeffrey A. Bluestone
Nature Medicine (2017) Vol. 23, Iss. 5, pp. 540-547
Closed Access | Times Cited: 405
CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
Kevin Pan, Hizra Farrukh, Veera Chandra Sekhar Reddy Chittepu, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 401
Next-generation regulatory T cell therapy
Leonardo M. R. Ferreira, Yannick D. Müller, Jeffrey A. Bluestone, et al.
Nature Reviews Drug Discovery (2019) Vol. 18, Iss. 10, pp. 749-769
Open Access | Times Cited: 388
CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity
Wenyan Fu, Changhai Lei, Shuowu Liu, et al.
Nature Communications (2019) Vol. 10, Iss. 1
Open Access | Times Cited: 374
Navigating CAR-T cells through the solid-tumour microenvironment
Andrew J. Hou, Laurence C. Chen, Yvonne Y. Chen
Nature Reviews Drug Discovery (2021) Vol. 20, Iss. 7, pp. 531-550
Open Access | Times Cited: 366
The Emerging Landscape of Immune Cell Therapies
Evan W. Weber, Marcela V. Maus, Crystal L. Mackall
Cell (2020) Vol. 181, Iss. 1, pp. 46-62
Open Access | Times Cited: 361
Programming CAR-T cells to kill cancer
Louai Labanieh, Robbie G. Majzner, Crystal L. Mackall
Nature Biomedical Engineering (2018) Vol. 2, Iss. 6, pp. 377-391
Open Access | Times Cited: 353
TGF-β signaling in health and disease
Joan Massagué, Dean Sheppard
Cell (2023) Vol. 186, Iss. 19, pp. 4007-4037
Open Access | Times Cited: 315
Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook
Chao Wang, Yanqi Ye, Quanyin Hu, et al.
Advanced Materials (2017) Vol. 29, Iss. 29
Closed Access | Times Cited: 276
Designing cell function: assembly of synthetic gene circuits for cell biology applications
Mingqi Xie, Martin Fussenegger
Nature Reviews Molecular Cell Biology (2018) Vol. 19, Iss. 8, pp. 507-525
Closed Access | Times Cited: 250
Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
Christian Flugel, Robbie G. Majzner, Giedre Krenciute, et al.
Nature Reviews Clinical Oncology (2022) Vol. 20, Iss. 1, pp. 49-62
Open Access | Times Cited: 239
Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity
Shengnan Yu, Ming Yi, Shuang Qin, et al.
Molecular Cancer (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 237
Programming gene and engineered-cell therapies with synthetic biology
Tasuku Kitada, Breanna DiAndreth, Brian Teague, et al.
Science (2018) Vol. 359, Iss. 6376
Open Access | Times Cited: 230
Digital logic circuits in yeast with CRISPR-dCas9 NOR gates
Miles Gander, Justin D. Vrana, William E. Voje, et al.
Nature Communications (2017) Vol. 8, Iss. 1
Open Access | Times Cited: 226
Exploiting Nanobodies’ Singular Traits
Jessica R. Ingram, Florian I. Schmidt, Hidde L. Ploegh
Annual Review of Immunology (2018) Vol. 36, Iss. 1, pp. 695-715
Closed Access | Times Cited: 223
Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward
Jian Li, Wenwen Li, Kejia Huang, et al.
Journal of Hematology & Oncology (2018) Vol. 11, Iss. 1
Open Access | Times Cited: 220
Expanding the Therapeutic Window for CAR T Cell Therapy in Solid Tumors: The Knowns and Unknowns of CAR T Cell Biology
Keisuke Watanabe, Shunichiro Kuramitsu, Avery D. Posey, et al.
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 220
Immune targets and neoantigens for cancer immunotherapy and precision medicine
Rong‐Fu Wang, Helen Y. Wang
Cell Research (2016) Vol. 27, Iss. 1, pp. 11-37
Open Access | Times Cited: 218
Understanding and treating the inflammatory adverse events of cancer immunotherapy
Michael Dougan, Adrienne Luoma, Stephanie K. Dougan, et al.
Cell (2021) Vol. 184, Iss. 6, pp. 1575-1588
Open Access | Times Cited: 207
Targeting Notch in oncology: the path forward
Samarpan Majumder, Judy S. Crabtree, Todd E. Golde, et al.
Nature Reviews Drug Discovery (2020) Vol. 20, Iss. 2, pp. 125-144
Closed Access | Times Cited: 204
CAR T‐cell therapy of solid tumors
Carmen S. Yong, Valérie Dardalhon, Christel Devaud, et al.
Immunology and Cell Biology (2016) Vol. 95, Iss. 4, pp. 356-363
Open Access | Times Cited: 202
Page 1 - Next Page

Scroll to top